Metastasis-free survival is a strong Surrogate of overall survival in localized prostate cancer

Journal of Clinical Oncology

Volumn 35, Issue 27, 2017, Pages 3097-3104

  Xie, Wanling ^a   Regan, Meredith M ^a   Buyse, Marc ^b   Halabi, Susan ^e   Kantoff, Philip ^p   Sartor, Oliver ^g   Soule, Howard ^h   Clarke, Noel W ^j   Collette, Laurence ^d   Dignam, James J ^l   Fizazi, Karim ^m   Paruleker, Wendy R ⁿ   Sandler, Howard M ⁱ   Sydes, Matthew R ^k   Tombal, Bertrand ^c   Williams, Scott G ^o,p   Sweeney, Christopher J ^a   Andren, Ove ^p   Armstrong, John ^p   Berry, Donald ^p   Bolla, Michel ^p   Chin, Joseph ^p   Chowdhury, Simon ^p   Clarke, Noel ^p   Cooperberg, Matthew ^p   Denham, Jim ^p   Dignam, James ^p   Di Stasi, Savino Mauro ^p   Eisenberger, Mario ^p   Freidlin, Boris ^p   Gillessen, Silke ^p   Gleave, Martin ^p   Habibian, Muriel ^p   James, Nicholas ^p   Jarow, Jonathan ^p   Keating, Nancy ^p   Keloff, Gary ^p   Klotz, Laurence ^p   Lukka, Himu ^p   Mason, Malcolm ^p   Miyahira, Andrea ^p   Mottet, Nicolas ^p   Nakabayashi, Mari ^p   Parulekar, Wendy R ^p   Regan, Meredith ^p   Sandler, Howard ^p   Scardino, Peter ^p   Scher, Howard ^p   Simon, Richard ^p   Simons, Jonathan ^p   Small, Eric ^p   Sydes, Matthew ^p   Tangen, Catherine ^p   Thompson, Ian ^p   Widmark, Anders ^p   Wiegel, Thomas ^p   Wirth, Manfred ^p   Yeoh, Eric ^p   Zapatero, Almudena ^p   more..

^a HARVARD MEDICAL SCHOOL   (United States)

^b International Drug Development Institute   (United States)

^c UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

^d EORTC DATA CENTER   (Belgium)

^e DUKE UNIVERSITY MEDICAL CENTER   (United States)

^f MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^g TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^h Prostate Cancer Foundation   (United States)

ⁱ CEDARS SINAI MEDICAL CENTER   (United States)

^j CHRISTIE HOSPITAL   (United Kingdom)

^k UNIVERSITY COLLEGE LONDON   (United Kingdom)

^l UNIVERSITY OF CHICAGO   (United States)

^m INSTITUT GUSTAVE ROUSSY   (France)

ⁿ Clinical Trials Group   (Canada)

^o PETER MACCALLUM CANCER CENTRE   (Australia)

^p NONE

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT;

AGED; ANDROGEN DEPRIVATION THERAPY; ARTICLE; CANCER LOCALIZATION; CANCER RADIOTHERAPY; CANCER SURGERY; CONTROLLED STUDY; CORRELATIONAL STUDY; DISEASE FREE SURVIVAL; FOLLOW UP; HIGH RISK PATIENT; HUMAN; INTERMEDIATE RISK PATIENT; MAJOR CLINICAL STUDY; MALE; METASTASIS FREE SURVIVAL; OVERALL SURVIVAL; PATIENT CODING; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; TREATMENT DURATION; BIOASSAY; META ANALYSIS; METASTASIS; MULTIMODALITY CANCER THERAPY; PATHOLOGY; PROSTATIC NEOPLASMS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK FACTOR; SURVIVAL ANALYSIS;

COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; ENDPOINT DETERMINATION; HUMANS; MALE; NEOPLASM METASTASIS; PROSTATIC NEOPLASMS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK FACTORS; SURVIVAL ANALYSIS;

EID: 85026843048     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2017.73.9987     Document Type: Article

References (22)

1. Torre LA, Bray F, Siegel RL, et al: Global cancer statistics, 2012. CA Cancer J Clin 65:87-108, 2015
2. Siegel RL, Miller KD, Jemal A: Cancer statistics, 2016. CA Cancer J Clin 66:7-30, 2016
3. Bolla M, Gonzalez D, Warde P, et al: Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. N Engl J Med 337:295-300, 1997
4. Denham JW, Steigler A, Lamb DS, et al: Shortterm neoadjuvant androgen deprivation and radiotherapy for locally advanced prostate cancer: 10-year data from the TROG 96.01 randomised trial. Lancet Oncol 12:451-459, 2011
5. Attard G, Parker C, Eeles RA, et al: Prostate cancer. Lancet 387:70-82, 2016
6. Sargent DJ, Wieand HS, Haller DG, et al: Disease-free survival versus overall survival as a primary end point for adjuvant colon cancer studies: Individual patient data from 20, 898 patients on 18 randomized trials. J Clin Oncol 23:8664-8670, 2005
7. Hamdy FC, Donovan JL, Lane JA, et al: 10-Year outcomes after monitoring, surgery, or radiotherapy for localized prostate cancer. N Engl J Med 375:1415-1424, 2016
8. Bill-Axelson A, Holmberg L, Garmo H, et al: Radical prostatectomy or watchful waiting in early prostate cancer. N Engl J Med 370:932-942, 2014
9. Crook JM, O'Callaghan CJ, Duncan G, et al: Intermittent androgen suppression for rising PSA level after radiotherapy. N Engl J Med 367:895-903, 2012
10. Ross AE, Yousefi K, Davicioni E, et al: Utility of risk models in decision making after radical prostatectomy: Lessons from a natural history cohort of intermediate- and high-risk men. Eur Urol 69:496-504, 2016
11. ICECaP Working Group, Sweeney C, Nakabayashi M, Regan M, et al: The development of Intermediate Clinical Endpoints in Cancer of the Prostate (ICECaP). J Natl Cancer Inst 107:djv261, 2015
12. Schweizer MT, Zhou XC, Wang H, et al: Metastasis-free survival is associated with overall survival in men with PSA-recurrent prostate cancer treated with deferred androgen deprivation therapy. Ann Oncol 24:2881-2886, 2013
13. Ciani O, Davis S, Tappenden P, et al: Validation of surrogate endpoints in advanced solid tumors: systematic review of statistical methods, results, and implications for policy makers. Int J Technol Assess Health Care 30:312-324, 2014
14. Buyse M, Michiels S, Squifflet P, et al: Leukemiafree survival as a surrogate end point for overall survival in the evaluation of maintenance therapy for patients with acute myeloid leukemia in complete remission. Haematologica 96:1106-1112, 2011
15. Buyse M, Molenberghs G, Burzykowski T, et al: The validation of surrogate endpoints in metaanalyses of randomized experiments. Biostatistics 1:49-67, 2000
16. Burzykowski T, Molenberghs G, Buyse M, et al: Validation of surrogate end points in multiple randomized clinical trials with failure time endpoints. Appl Stat 50:405-422, 2001
17. Fine J, Gray R: A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc 94:496-509, 1999
18. Burzykowski T, Buyse M: Surrogate threshold effect: An alternative measure for meta-analytic surrogate endpoint validation. Pharm Stat 5:173-186, 2006
19. Shipley WU, Seiferheld W, Lukka HR, et al: Radiation with or without antiandrogen therapy in recurrent prostate cancer. N Engl J Med 376:417-428, 2017
20. Messing EM, Manola J, Sarosdy M, et al: Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer. N Engl J Med 341:1781-1788, 1999
21. Messing EM, Manola J, Yao J, et al: Immediate versus deferred androgen deprivation treatment in patients with node-positive prostate cancer after radical prostatectomy and pelvic lymphadenectomy. Lancet Oncol 7:472-479, 2006
22. Bolla M, Van Tienhoven G, Warde P, et al: External irradiation with or without long-term androgen suppression for prostate cancer with high metastatic risk: 10-year results of an EORTC randomised study. Lancet Oncol 11:1066-1073, 2010